STERIS plc (STE) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 1.28B USD | Liabilities, Current |
| Cash and equivalents | 482.30M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 1.01B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 712.10M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.28B | $482.30M | (m) | $1.01B | $712.10M | (m) |
| 2026-03-31 | (m) | $1.15B | (m) | (m) | $1.09B | $631.80M | (m) |
| 2025-12-31 | (m) | $922.30M | $423.70M | (m) | $990.60M | $673.50M | (m) |
| 2025-09-30 | (m) | $888.90M | $319.20M | (m) | $947.30M | $658.50M | (m) |
| 2025-06-30 | (m) | $926.60M | $279.70M | (m) | $947.10M | $641.20M | (m) |
| 2025-03-31 | (m) | $1.02B | (m) | (m) | $1.04B | $581.33M | (m) |
| 2024-12-31 | (m) | $891.12M | $155.18M | (m) | $915.20M | $649.56M | (m) |
| 2024-09-30 | (m) | $805.48M | $172.19M | (m) | $923.34M | $688.93M | (m) |
| 2024-06-30 | (m) | $834.36M | $198.33M | (m) | $892.61M | $698.59M | (m) |
| 2024-03-31 | (m) | $931.13M | (m) | (m) | $1.01B | $674.53M | (m) |
| 2023-12-31 | (m) | $913.69M | $195.59M | (m) | $964.02M | $855.62M | (m) |
| 2023-09-30 | (m) | $873.12M | $213.76M | (m) | $940.33M | $821.13M | (m) |
| 2023-06-30 | (m) | $886.91M | $208.61M | (m) | $887.76M | $768.84M | (m) |
| 2023-03-31 | (m) | $861.84M | (m) | (m) | $928.32M | $695.49M | (m) |
| 2022-12-31 | (m) | $796.46M | $259.37M | (m) | $822.76M | $694.36M | (m) |
| 2022-09-30 | (m) | $872.82M | $258.26M | (m) | $780.11M | $644.94M | (m) |
| 2022-06-30 | (m) | $908.32M | $316.33M | (m) | $763.79M | $620.40M | (m) |
| 2022-03-31 | (m) | $922.22M | (m) | (m) | $799.04M | $575.00M | (m) |
| 2021-12-31 | (m) | $904.31M | $359.09M | (m) | $752.13M | $594.60M | (m) |
| 2021-09-30 | (m) | $785.70M | $383.49M | (m) | $762.00M | $564.53M | (m) |
| 2021-06-30 | (m) | $1.15B | $534.77M | (m) | $743.42M | $593.07M | (m) |
| 2021-03-31 | (m) | $577.92M | $220.53M | (m) | $609.41M | $315.07M | (m) |
| 2020-12-31 | (m) | $505.87M | $252.50M | (m) | $556.12M | $294.13M | (m) |
| 2020-09-30 | (m) | $435.42M | $312.03M | (m) | $503.72M | $278.59M | (m) |
| 2020-06-30 | (m) | $479.55M | $255.63M | (m) | $503.17M | $276.97M | (m) |
| 2020-03-31 | (m) | $503.61M | $319.58M | (m) | $586.48M | $248.26M | (m) |
| 2019-12-31 | (m) | $450.81M | $199.23M | (m) | $544.40M | $252.05M | (m) |
| 2019-09-30 | (m) | $428.02M | $225.54M | (m) | $513.35M | $236.84M | (m) |
| 2019-06-30 | (m) | $432.77M | $238.07M | (m) | $509.65M | $233.59M | (m) |
| 2019-03-31 | (m) | $465.20M | $220.63M | (m) | $564.83M | $208.24M | (m) |
| 2018-12-31 | (m) | (m) | $224.91M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | $209.92M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $218.52M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $398.46M | $201.53M | (m) | $528.07M | $205.73M | (m) |
| 2017-03-31 | (m) | (m) | $282.92M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | $248.84M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |
| Conexeu Sciences Inc. (CNXU) | United States | $0.111B |